The healthcare and life sciences sectors are now bracing for global ripple effects as the Trump administration, under President Donald J. Trump’s second term, enforces a new round of tariffs targeting imports from key trade partners, including India and China. The proposed 25% tariff on
POST TAGS:
25% tariffAmerica FirstAssociation of Indian Medical Device Industry (AiMeD)Chairman Medical Technology Association of IndiaChinaDonald J. TrumpExecutive Chairman and Managing Director of OmniActive Health TechnologiesForum CoordinatorIndian pharmaceuticalMedical DevicesMr. Bhavin MukundMr. Rajiv NathMr. Sanjaya MariwalaPavan ChoudaryPharmacy of the WorldRussiaU.S. FDAVice Chairman of Pharmexcil and Whole Time Director at Kilitch DrugsViksit Bharat
